APR 22, 2019 12:00 AM PDT

Direct Oral Anti-Coagulant (DOAC) Measurement Focusing on Anti-Xa, and Recent DOAC Trial Updates

Sponsored by: Diagnostica Stago, Inc.
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Chair and Professor, Medicine (primary) Professor, Clinical Epidemiology and Biostatistics (Associate) Leo Pharma Chair in Thromboembolism Research
    Biography
      Dr Crowther's research interests include improving the way we use current anticoagulant drugs. These include exploring established and novel interventions to mitigate bleeding, and studies of currently available anticoagulant drugs in high-risk patient populations. Dr Crowther's work also focusses on developing systematic reviews of key questions in Hematology and Thrombosis, and basing Guidelines on those reviews.

      Dr Crowther has more than 400 peer reviewed publications, was inducted into the Royal Society of Canada in 2017, and received the 2017 International Society of Thrombosis and Haemostasis BACH Investigator Recognition Award. He was one of 14 scientists from the Michael G. DeGroote School of Medicine at McMaster University cited by Clarivate Analytics on its Highly Cited Researchers list (formerly known as Thomson Reuter's annual publication of The World's Most Influential Scientific Minds).

      Dr Crowther is currently the Chair, Department of Medicine at McMaster University and holds the Leo Pharma Chair in Thromboembolism Research at McMaster University.

    Abstract:

    Have you ever wondered about the impact of direct oral anticoagulants (DOACs) on routine coagulation assays and how patients on DOACs can be managed by the clinical laboratory? DOACs have been available for several years to treat atrial fibrillation patients at risk of stroke, as well as patients with venous thromboembolism (VTE). Though routine monitoring is not required for patients taking DOACs, screening or measurement assays could help in some emergency patient management situations. Dr Crowther’s webinar will cover this hot topic, which regularly impacts patients in critical care settings.

    Learning objectives:

    • Highlight recent clinical trials describing use of DOACs
    • Present situations for which DOAC monitoring can help in the picture of patient care
    • Review best practice with respect to DOAC measurement

     


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    AUG 27, 2019 9:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 9:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    DEC 05, 2019 5:00 AM PST
    C.E. CREDITS
    DEC 05, 2019 5:00 AM PST
    DATE: December 5, 2019TIME: 5:00am PST, 8:00am EST The diagnosis of an active infection by the hepatitis B virus (HBV) relies on testing for the HBV surface antigen (HBsAg). Ov...
    SEP 27, 2019 9:00 AM PDT
    C.E. CREDITS
    SEP 27, 2019 9:00 AM PDT
    DATE: September 27, 2019TIME: 9:00am PT, 12:00pm ET Thienopyrazole derivatives have recently emerged as effective antitumoral agents with kinase inhibitory activity. In this s...
    Loading Comments...
    Show Resources